ArticleFrontiers in oncology2025
Case Report: An ovarian epithelial-type serous adenocarcinoma of the testis was treated using systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian-type serous adenocarcinoma of the testis is an extremely rare malignant disease, and experience and evidence regarding its treatment are lacking. Herein, we describe the case of a 39-year-old man who presented with widespread metastasis in the retroperitoneal and pelvic lymph nodes after surgical resection of his right testicular tumor. Systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous adenocarcinoma, was administered, and retroperitoneal lymph node dissection and radiotherapy followed after the lesions regressed. The patient has had over 3 years of progression-free survival. This is the first case of a bevacizumab combination in this disease and indicates that bevacizumab may be an option for the treatment strategy of this rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.